Technologies
PDF


WARF: P160384US02

Use of Salate Derivatives to Treat Multiple Sclerosis


INVENTORS -

Hector DeLuca, Lori Plum, Steven Marling, Yanping Wang

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing new therapeutic compounds to treat multiple sclerosis (MS). A team led by Prof. Hector DeLuca has shown that homosalate and octyl salicylate – ingredients commonly found in sunscreen – can dramatically suppress disease progression in EAE mice, a widely used animal model of MS.

Salate derivatives therefore may be useful in preventing or arresting the symptoms of MS, and provide new insights into mechanisms of controlling autoimmune disease.
OVERVIEWMultiple sclerosis (MS) is a chronic inflammatory autoimmune disease affecting 2.5 million people worldwide. The disease is difficult to manage and there is no cure. The underlying mechanism of MS progression is thought to be either destruction by the immune system or failure of myelin-producing cells. The cause of the disease is not known.

Current treatments attempt to improve symptoms after an attack and prevent new attacks. Medications are only modestly effective and may have side effects and be poorly tolerated. Life expectancy is five to 10 years lower than that of the unaffected population.
THE INVENTIONUW–Madison researchers led by Prof. Hector DeLuca have discovered that two specific salate esters commonly found in sunscreen almost completely prevented experimental autoimmune encephalomyelitis (EAE) development in mice without affecting body weight. Salicylates are well-known nonsteroidal anti-inflammatory drugs (NSAIDs); the complete suppression of EAE by topical administration of homosalate and octyl salicylate is a novel finding.
APPLICATIONS
  • Treatment of multiple sclerosis
KEY BENEFITS
  • Preclinical results in a mouse model indicate effectiveness without adverse effects.
STAGE OF DEVELOPMENTFigure 3A from the patent application (bottom) shows that homosalate and octyl salicylate suppress EAE development in the mouse model of MS. When tested directly both salates were equally active at ca. 1.5 g/kg in suppressing EAE. The only adverse effect observed was a temporary mild skin irritation.
Contact Information
For current licensing status, please contact John Nagel at jnagel@warf.org or 608-960-9848.
FIGURES

Sunscreen ingredients suppress disease progression in a mouse model of MS. Sunscreen ingredients suppress disease progression in a mouse model of MS.


The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.